^
9h
Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial. (PubMed, Clin Cancer Res)
TILT-123 was safe and able to produce anti-tumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, NCT06125197).
P1 data • Journal • Oncolytic virus • Metastases
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
igrelimogene litadenorepvec (TILT-123)
10h
Exploring gene biomarkers and targeted drugs for ferroptosis and cuproptosis in osteosarcoma: A bioinformatic approach. (PubMed, Environ Toxicol)
PCR analysis showed increased mRNA levels of the genes FDX1 and SQLE in osteosarcoma tissues. This study elucidates the interaction of ferroptosis and cuproptosis genes in osteosarcoma and paves the way for more targeted immunotherapy.
Journal • IO biomarker
|
FDX1 (Ferredoxin 1)
10h
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. (PubMed, JAMA Netw Open)
Other important clinical findings included that individuals with TP53 had poor outcomes independent of second malignant neoplasms and that patients with fusion-negative rhabdomyosarcoma who harbored a CPV had outcomes comparable to patients with fusion-positive rhabdomyosarcoma. These findings suggest that germline CPV testing may aid in clinical prognosis and should be considered in prospective risk-based clinical trials.
Journal
|
TP53 (Tumor protein P53) • PAX3 (Paired Box 3) • PAX7 (Paired Box 7)
13h
Identification of allograft inflammatory factor-1 suppressing the progression and indicating good prognosis of osteosarcoma. (PubMed, BMC Musculoskelet Disord)
In conclusion, DEGs and hub genes identified in the present study help us understand the molecular mechanisms underlying the carcinogenesis and progression of osteosarcoma, and provide candidate targets for diagnosis and treatment of osteosarcoma.
Journal
|
AIF1 (Allograft Inflammatory Factor 1)
13h
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. (PubMed, Pharmaceutics)
AgNP was able to selectively remove pNF cells from a co-culture with patient-matched Schwann cells. Therefore, AgNPs represent a new approach for clinical management of NF1-associated pNF to address significant clinical need.
Journal
|
NF1 (Neurofibromin 1)
|
NF1 mutation
14h
Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations. (PubMed, Molecules)
The discovered noncovalent KRASG12D inhibitors exhibit promises as potential candidates for targeted therapy against KRASG12D-driven cancers. This comprehensive computational framework not only expedites the discovery of novel KRASG12D inhibitors but also provides valuable insights for the development of precision treatments tailored to this oncogenic mutation.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12D + KRAS G12V
14h
Ferroptosis Altered microRNAs Expression in HT-1080 Fibrosarcoma Cells Based on Small RNA Sequencing and Bioinformatics Analysis. (PubMed, Nutrients)
hsa-miR-200c-3p, hsa-miR-26b-5p, and hsa-miR-7-5p were filtered out. Comprehensive bioinformatics analysis of miRNAs and its upstream and downstream regulation in ferroptosis in HT-1080 cells using small RNA sequencing is helpful for understanding the role of miRNAs in iron overload-related diseases and ferroptosis-targeted therapy for cancer.
Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR200C (MicroRNA 200c) • MIR7 (MicroRNA 7) • SNCA (Synuclein Alpha)
15h
Cell-Type-Dependent Recruitment Dynamics of FUS Protein at Laser-Induced DNA Damage Sites. (PubMed, Int J Mol Sci)
Our work suggests a cell-type-dependent recruitment behavior of FUS during the DNA damage response and repair procedure. The presented workflow might be a valuable tool for studying the proteins recruited at the DNA damage site in a real-time course.
Journal
|
FUS (FUS RNA Binding Protein)
15h
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. (PubMed, Int J Mol Sci)
Moreover, the phase III CodeBreaK 300 trial demonstrates the superiority of sotorasib-panitumumab over trifluridine/tipiracil, establishing a new standard of care for patients with colorectal cancer harboring KRAS G12C mutations. Other combinations such as adagrasib-cetuximab, divarasib-cetuximab, or FOLFIRI-panitumumab-sotorasib have also shown a meaningful response rate and are currently under evaluation...In this setting, liquid biopsy emerges as a critical tool to characterize the mechanisms of resistance, consisting mainly of acquired genomic alterations in the MAPK and PI3K pathways and tyrosine kinase receptor alterations, but gene fusions, histological changes, or conformational changes in the kinase have also been described. In this paper, we review the development of KRAS G12C inhibitors in colorectal cancer as well as the main mechanisms of resistance.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • Krazati (adagrasib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • divarasib (RG6330)
16h
Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. (PubMed, J Clin Med)
However, histone acetylation may be one of the epigenetic mechanisms involved in PRAME regulation. Thus, the therapeutic combination of histone deacetylase inhibitors and PRAME immunotherapy merits further investigation.
Journal • IO biomarker • Epigenetic controller
|
DNMT3A (DNA methyltransferase 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
17h
Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies. (PubMed, J Pers Med)
The present review offers a comprehensive analysis of targeted therapeutics for skull base chondrosarcomas, highlighting a complex landscape characterized by a range of treatment approaches and new opportunities for tailored interventions. The combination of results from molecular research and clinical trials emphasizes the necessity for specialized treatment strategies and the complexity of chondrosarcoma biology.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • COL2A1 (Collagen Type II Alpha 1 Chain)
|
MG132
18h
A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies. (PubMed, Genes (Basel))
We advocate testing for this variant in high-risk patients of AJ descent. The inclusion of POT1 in germline panels for various types of cancer is warranted.
Journal
|
POT1 (Protection of telomeres 1)
19h
Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells. (PubMed, Cancers (Basel))
Additionally, knockdown of SS18-SSX, which upregulates BCL2, reduced the sensitivity to ABBV-075. These findings suggest the potential utility of BET inhibitors targeting the SS18-SSX-regulated intrinsic apoptotic pathway as a promising therapeutic strategy for SS.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDK4 (Cyclin-dependent kinase 4) • BCL2L1 (BCL2-like 1) • CDK6 (Cyclin-dependent kinase 6) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
|
mivebresib (ABBV 075)
19h
Estrogen Receptor Expression in DICER1-related Lesions is Associated with the Presence of Cystic Components. (PubMed, Am J Surg Pathol)
Lesions not associated with DICER1 pathogenic variants also showed ER-positive stromal cells, including cystic pulmonary airway malformations, cystic renal dysplasia, and simple renal cysts in adult kidneys. ER expression in stromal cells is not a feature of DICER1 perturbation but rather is related to the presence of cystic components.
Journal
|
ER (Estrogen receptor) • PRAME (Preferentially Expressed Antigen In Melanoma) • DICER1 (Dicer 1 Ribonuclease III)
|
ER positive • ER expression • PRAME expression
20h
Identification of an early survival prognostic gene signature for localized osteosarcoma patients. (PubMed, Sci Rep)
Subsequently, we demonstrated that GLI antagonists inhibited growth of a recurrent localized PDX-derived cell line with elevated IHH and GLI1 expression, but not a non-relapsed cell line with low pathway activation. Finally, we show that our signature outperforms previously reported signatures in predicting poor prognosis and death within 3 years in patients with localized osteosarcoma.
Journal • Gene Signature
|
GLI1 (GLI Family Zinc Finger 1)
|
GLI1 expression
20h
Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib. (PubMed, NPJ Genom Med)
Multifocal GISTs in the proband and her mother were treated with preoperative imatinib, which resulted in severe intolerance. The clinical features of multifocal GIST, cutaneous mastocytosis, allergies, and gut motility disorders seen in the affected individuals may represent manifestations of the multifunctional roles of KIT in interstitial cells of Cajal or mast cells and/or may be suggestive of additional molecular pathways which can contribute to tumorigenesis.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • MSR1 (Macrophage Scavenger Receptor 1)
|
imatinib
1d
CEB-01-RLS01-CT: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov)
P1, N=21, Active, not recruiting, CEBIOTEX | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • Surgery • Metastases
|
CEB-01
1d
TRuST: A Study to Assess the Long-term Safety of Tazemetostat (clinicaltrials.gov)
P1/2, N=100, Enrolling by invitation, Epizyme, Inc. | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
Tazverik (tazemetostat)
1d
Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma. (PubMed, Anticancer Res)
Expression levels of MMP2 and MMP9 were upregulated in malignant uLMS tumors when compared with those in benign uterine leiomyoma tumors. Increased MMP2 expression might promote uLMS invasion and migration. MMP9 overexpression might be related to uLMS occurrence; however, it protects against uLMS invasion and metastasis. MMP2 and MMP9 may be potential predictors of uLMS cell proliferation, metastasis, and prognosis. These findings could be helpful in developing new strategies for diagnosing and treating uLMS.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
MMP9 overexpression
1d
Malignant peripheral nerve sheath tumour with divergent epithelioid differentiation in a cat. (PubMed, J Comp Pathol)
Melanoma-associated antigen, desmin, α-smooth muscle actin, CD18, CD31, ionized calcium binding adapter molecule-1 and CK8/18 were not expressed, which helped differentiate the tumour from other feline spindloid cell neoplasms. These features are characteristic of divergent epithelioid differentiation of MPNST.
Journal
|
VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ITGB2 (Integrin Subunit Beta 2) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • GFAP (Glial Fibrillary Acidic Protein)
1d
Netrin-1 Role in Nociceptive Neuron Sprouting through Activation of DCC Signaling in a Rat Model of Bone Cancer Pain. (PubMed, J Integr Neurosci)
Netrin-1 may contribute to the activation of the BCP by inducing nociceptive nerve innervation and improving pain behaviors.
Preclinical • Journal
|
RAC1 (Rac Family Small GTPase 1) • CDC42 (Cell Division Cycle 42) • NTN1 (Netrin 1)
1d
METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4. (PubMed, Front Biosci (Landmark Ed))
These results suggest that the combined action of METTL3 and CBX4 plays an important role in the regulation of metastasis of osteosarcoma, and therefore, the METTL3-CBX4 axis pathway may be a new potential therapeutic target for osteosarcoma.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • METTL3 (Methyltransferase Like 3)
|
CDH1 expression
1d
Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers. (PubMed, Clin Cancer Res)
sWGS and targeted sequencing identified therapeutic opportunities in 75% of p53abn EC patients. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn ECs.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HRD (Homologous Recombination Deficiency) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
|
TP53 mutation • BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • HRD • MYC amplification • CCNE1 amplification • HRD + BRCA1 mutation • HRD signature
1d
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells. (PubMed, J Immunother Cancer)
This study demonstrated the safety of GD2BATs up to 160×106 cells/kg/infusion. Coupled with evidence of post-treatment endogenous immune responses, our findings support further investigation of GD2BATs in larger phase II clinical trials.
Clinical Trial,Phase II • Journal
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2)
1d
Anti-CD99 Antibody Therapy Triggers Macrophage-Dependent Ewing Cell Death In Vitro and Myeloid Cell Recruitment In Vivo. (PubMed, Antibodies (Basel))
These studies are the first to demonstrate the role of human immune effector cells in anti-CD99-mediated Ewing tumor death. We propose that the engagement of CD99 by NOA2 results in the recruitment of intratumoral macrophages. In addition, interruption of the CD99:PILRα checkpoint axis may be a relevant therapeutic approach to activate tumor-associated macrophages.
Preclinical • Journal
|
CD99 (CD99 Molecule)
1d
Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients. (PubMed, Heliyon)
Additionally, PCOLCE may exert its roles via several immune-related biological processes or pathways, such as leukocyte migration, activation of T cells, adaptive immune response, neutrophil-mediated immunity, NF-κB, and TNF signaling pathways. In conclusion, PCOLCE may be a new immune-related gene and regulate tumor development through immunological pathways.
Journal
|
CD4 (CD4 Molecule)
1d
The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis. (PubMed, iScience)
This first systematic comparison between LARP4A and LARP4B assigns new pro-tumorigenic functions to LARP4A and LARP4B in bone and prostate cancer, highlighting their similarities while also indicating distinct functional differences. Uncovering clear biological roles for these paralogous proteins provides new avenues for identifying tissue-specific targets and potential druggable intervention.
Journal
|
E2F1 (E2F transcription factor 1)
1d
BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. (PubMed, J Bone Oncol)
Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET)...More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo. Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
Focus V (anlotinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • metatinib tromethamine (BMS-794833)
1d
Follicular dendritic cell sarcoma arising from the lymph node of the pancreatic head: a case report with literature review. (PubMed, Clin J Gastroenterol)
Intraperitoneal nodal FDCS is extremely rare, and occasionally, it can lead to postoperative recurrence and progression. It is crucial to differentiate neoplastic lymph node enlargement around the pancreatic head from nodal FDCS.
Review • Journal
|
FCER2 (Fc Fragment Of IgE Receptor II)
1d
Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma. (PubMed, Sci Rep)
Finally, the SLC7A11/hsa-miR-29c-3p/LINC00511, and RPN1/hsa-miR-143-3p/LINC00511 regulatory axes were constructed. This study provided DRG riskscore signatures to predict prognosis and response to immunotherapy in SARC, guiding personalized treatment decisions.
Journal • Gene Signature • IO biomarker
|
SLC7A11 (Solute Carrier Family 7 Member 11) • MIR143 (MicroRNA 143)
1d
USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/AKT signaling pathway. (PubMed, Cell Death Dis)
And knockdown of EPHA2 expression reversed the pro-tumour effects of USP3-upregulating. Thus, our study indicates the USP3/EPHA2 axis may be a novel potential target for OS treatment.
Journal
|
EPHA2 (EPH receptor A2)
2d
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors (clinicaltrials.gov)
P1, N=0, Withdrawn, St. Jude Children's Research Hospital | N=52 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
Xpovio (selinexor) • idasanutlin (RG7388)
2d
New P2 trial • Metastases
|
cisplatin • carboplatin • 5-fluorouracil • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • Jemperli (dostarlimab-gxly)
2d
UMBRELLA: tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (clinicaltrials.gov)
P3, N=717, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris
New P3 trial
|
Tevimbra (tislelizumab)
2d
NCI-2018-01928: CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma (clinicaltrials.gov)
P1, N=7, Terminated, Roswell Park Cancer Institute | N=36 --> 7 | Trial completion date: Aug 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2024; low accrual
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
2d
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas. (PubMed, Eur J Cancer)
We detected (de novo/somatic) missense mutation variants in cis position of the NTRK1 gene in a subset of DDLPS indicating modifying mutations that may contribute to tumorigenesis in a subset of DDLPS. These variants beget resistance to TRK inhibitors indicating an interesting biomarker for other studies with TRK inhibitors.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 mutation • NTRK fusion
|
Vitrakvi (larotrectinib) • selitrectinib (BAY 2731954)
3d
Spindle cell neoplasms with novel LTK fusion - Expanding the spectrum of kinase fusion-positive soft tissue tumors. (PubMed, Genes Chromosomes Cancer)
This is the first reported case series of soft tissue tumors harboring LTK fusion, expanding the molecular landscape of soft tissue tumors driven by activating kinase fusions. Furthermore, studies involving a larger number of cases and integrated genomic analyses will be warranted to fully elucidate the pathogenesis and classification of these tumors.
Journal
|
CD34 (CD34 molecule) • LTK (Leukocyte Receptor Tyrosine Kinase)
3d
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. (PubMed, J Clin Invest)
Hence, aberrantly expressed ETS proteins derepress pericentromeric heterochromatin, yielding pathogenic RNAs which transmit genotoxic stress and inflammation to local and distant sites. Monitoring HSAT2,3 plasma levels and preventing their dissemination may thus improve therapeutic strategies and blood-based diagnostics.
Journal
|
ERG (ETS Transcription Factor ERG) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • TMPRSS2 (Transmembrane serine protease 2)
3d
Gentiopicroside ameliorates the lipopolysaccharide-induced inflammatory response and hypertrophy in chondrocytes. (PubMed, J Orthop Surg Res)
Our study demonstrated that GPS significantly inhibited the LPS-induced inflammatory response and hypertrophic cellular degeneration in SW 1353 chondrosarcoma cells and is a valuable traditional Chinese medicine for the treatment of knee osteoarthritis.
Journal
|
IL1B (Interleukin 1, beta) • RUNX2 (RUNX Family Transcription Factor 2)
3d
Trial initiation date • Metastases
|
MDM2 (E3 ubiquitin protein ligase)
|
MDM2 amplification
|
brigimadlin (BI 907828)
3d
BETA-PRIME: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (clinicaltrials.gov)
P2, N=140, Recruiting, EpicentRx, Inc. | Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
TGFB1 (Transforming Growth Factor Beta 1)
|
AIM-001
3d
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
P1, N=24, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
CD4 (CD4 Molecule)
|
paclitaxel • Neupogen (filgrastim)